Incyte Corp. (INCY)

Precedente Chiudi:

$51.18

Aprire:

$50.99

Volume 24 ore:

1.55M

Capitalizzazione di mercato:

$11.60B

Reddito:

$3.70B

Utile/perdita netta:

$597.60M

Rapporto P/E:

27.34

EPS:

1.89

Flusso di cassa netto:

$449.00M

1 W Prestazione:

-1.28%

1M Prestazione:

-8.61%

6M Prestazione:

-4.77%

1 anno Prestazione:

-29.72%

Intervallo 1D:

$50.87

$51.85

Portata 52W:

$50.27

$75.74

Incyte Corp. Stock (INCY) Company Profile

Nome

Incyte Corp.

Settore

Healthcare (1191)

Industria

Biotechnology (688)

Telefono

302-498-6700

Indirizzo

1801 Augustine Cut-Off, Wilmington, DE

Dipendente

1,208

Cinguettio

@Incyte

Prossima data di guadagno

2024-04-30

Ultimi documenti SEC

INCY's Discussions on Twitter

Incyte Corp. Stock (INCY) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-02-14	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
2023-12-13	Aggiornamento	Leerink Partners	Market Perform → Outperform
2023-12-04	Aggiornamento	Guggenheim	Neutral → Buy
2023-11-21	Downgrade	Goldman	Buy → Neutral
2023-07-25	Iniziato	Citigroup	Buy
2023-05-04	Downgrade	BofA Securities	Buy → Neutral
2023-04-10	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2023-03-24	Aggiornamento	SVB Securities	Underperform → Market Perform
2023-01-31	Iniziato	Piper Sandler	Overweight
2022-08-03	Downgrade	Evercore ISI	Outperform → In-line
2022-08-03	Downgrade	Guggenheim	Buy → Neutral
2022-07-28	Iniziato	Wells Fargo	Equal Weight
2022-02-09	Downgrade	SVB Leerink	Mkt Perform → Underperform
2022-01-18	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2021-11-19	Iniziato	BMO Capital Markets	Market Perform
2021-07-20	Aggiornamento	The Benchmark Company	Hold → Buy
2021-02-10	Downgrade	SVB Leerink	Mkt Perform → Underperform
2021-01-07	Iniziato	Truist	Buy
2021-01-04	Aggiornamento	Guggenheim	Neutral → Buy
2020-06-16	Iniziato	The Benchmark Company	Hold
2020-05-06	Downgrade	JP Morgan	Overweight → Neutral
2020-04-29	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2020-04-01	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2020-03-24	Ripresa	William Blair	Outperform
2020-03-13	Aggiornamento	BofA/Merrill	Neutral → Buy
2020-02-04	Ripresa	BofA/Merrill	Neutral
2020-01-03	Reiterato	BMO Capital Markets	Market Perform
2020-01-03	Downgrade	Mizuho	Buy → Neutral
2020-01-02	Downgrade	Guggenheim	Buy → Neutral
2019-10-03	Iniziato	Mizuho	Buy
2019-09-12	Iniziato	BMO Capital Markets	Market Perform
2019-09-05	Aggiornamento	JMP Securities	Mkt Perform → Mkt Outperform
2019-09-05	Ripresa	Morgan Stanley	Equal-Weight
2019-09-05	Aggiornamento	Oppenheimer	Perform → Outperform
2019-05-21	Iniziato	Credit Suisse	Neutral
2019-05-03	Downgrade	Barclays	Overweight → Equal Weight
2019-04-11	Iniziato	Stifel	Hold
2019-04-03	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2019-01-24	Aggiornamento	William Blair	Mkt Perform → Outperform

Mostra tutto

Incyte Corp. Borsa (INCY) Ultime notizie

The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals

Zacks Investment Research

Biotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates from VRTX

Zacks Investment Research

Allogene Therapeutics (ALLO) Expected to Beat Earnings Estimates: Should You Buy?

Zacks Investment Research

Incyte Should Consider Significant Stock Buyback And Prioritize R&D, Analyst Recommends

Benzinga

Peeling Back The Layers: Exploring Incyte Through Analyst Insights

Benzinga

Incyte (INCY) Earnings Expected to Grow: Should You Buy?

Zacks Investment Research

Incyte Corp. Azioni (INCY) Dati Finanziari

Incyte Corp. (INCY) Reddito 2024

Incyte Corp. (INCY) Reddito netto 2024

Incyte Corp. (INCY) Flusso di cassa 2024

Incyte Corp. (INCY) Utile per azione 2024